Inovio to Present ASGCT Hemophilia A Gene Transfer Data and INO-3107 Results
Inovio will present hemophilia A gene transfer correction data in mice at the ASGCT meeting on May 12 and B cell response results for recurrent respiratory papillomatosis patients treated with INO-3107 at the ASCO meeting on May 30. Abstracts will be posted on Inovio’s website after presentations.
1. Conference Participation
Inovio will attend the American Society of Gene and Cell Therapy meeting in Boston on May 12 and the American Society of Clinical Oncology meeting in Chicago on May 30. Presentation times are scheduled from 5:00 to 6:30 PM ET in Boston and 1:30 to 4:30 PM CDT in Chicago.
2. Hemophilia A Gene Transfer Data
A poster titled “Bleeding phenotype correction in hemophilia A mice following in vivo Factor VIII gene transfer by electroporation in skeletal muscle cells” will detail preclinical efficacy data, highlighting improvements in clotting function in treated mice.
3. INO-3107 Clinical Poster
A second poster will present B cell responses in patients with recurrent respiratory papillomatosis treated with DNA immunotherapy INO-3107, offering insights into immune activation and potential therapeutic benefit in HPV-related disease.
4. Abstract Access and Outlook
Available abstracts will be posted on Inovio’s website following each conference. These presentations could build momentum for the company’s pipeline assets and inform investor and partner evaluation of its DNA medicine platform.